Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies

被引:158
|
作者
Mueller, Paula [1 ,2 ]
Lemcke, Heiko [1 ,2 ]
David, Robert [1 ,2 ]
机构
[1] Rostock Univ, Med Ctr, Dept Cardiac Surg, Reference & Translat Ctr Cardiac Stem Cell Theray, Rostock, Germany
[2] Rostock Univ, Dept Life Light & Matter, Interdisciplinary Fac, Rostock, Germany
关键词
Mesenchymal stem cells; Cardiovascular diseases; Cell replacement; Cardiac regeneration; Stem cell modification; ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR FUNCTION; BONE-MARROW-CELLS; CARDIAC PROGENITOR CELLS; SKELETAL MYOBLAST TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NONISCHEMIC DILATED CARDIOMYOPATHY; CARDIOSPHERE-DERIVED CELLS; COLONY-STIMULATING FACTOR; HUMAN ADIPOSE-TISSUE;
D O I
10.1159/000492704
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A large number of clinical trials have shown stem cell therapy to be a promising therapeutic approach for the treatment of cardiovascular diseases. Since the first transplantation into human patients, several stem cell types have been applied in this field, including bone marrow derived stem cells, cardiac progenitors as well as embryonic stem cells and their derivatives. However, results obtained from clinical studies are inconsistent and stem cell-based improvement of heart performance and cardiac remodeling was found to be quite limited. In order to optimize stem cell efficiency, it is crucial to elucidate the underlying mechanisms mediating the beneficial effects of stem cell transplantation. Based on these mechanisms, researchers have developed different improvement strategies to boost the potency of stem cell repair and to generate the "next generation" of stem cell therapeutics. Moreover, since cardiovascular diseases are complex disorders including several disease patterns and pathologic mechanisms it may be difficult to provide a uniform therapeutic intervention for all subgroups of patients. Therefore, future strategies should aim at more personalized SC therapies in which individual disease parameters influence the selection of optimal cell type, dosage and delivery approach. (C) 2018 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:2607 / 2655
页数:49
相关论文
共 50 条
  • [41] Stem cell therapy for retinal diseases: update
    Siqueira, Rubens Camargo
    STEM CELL RESEARCH & THERAPY, 2011, 2
  • [42] Pluripotent stem cell therapy for retinal diseases
    Ahmed, Ishrat
    Johnston, Robert J., Jr.
    Singh, Mandeep S.
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (15)
  • [43] Update on stem cell therapy of autoimmune diseases
    Tyndall, A. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 39 - 39
  • [44] Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases
    Chen, Lukui
    Qiu, Rong
    Xu, Qiang
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2014, 14 (01) : 969 - 975
  • [45] Cardiac cell-based therapy: Cell types and mechanisms of actions
    Ramos, Geraldo A.
    Hare, Joshua M.
    CELL TRANSPLANTATION, 2007, 16 (09) : 951 - 961
  • [46] Neural stem cell therapy in neurological diseases
    Uyanikgil, Yigit
    Balcioglu, Huseyin Avni
    ARCHIVES OF MEDICAL SCIENCE, 2009, 5 (03) : 296 - 302
  • [47] Mesenchymal stem cell therapy for corneal diseases
    Shukla, Sachin
    Tavakkoli, Fatemeh
    Singh, Vivek
    Sangwan, Virender Singh
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (09): : 917 - 926
  • [48] Mesenchymal Stem Cell Therapy and Lung Diseases
    Akram, Khondoker M.
    Samad, Sohel
    Spiteri, Monica
    Forsyth, Nicholas R.
    MESENCHYMAL STEM CELLS: BASICS AND CLINICAL APPLICATION II, 2013, 130 : 105 - 129
  • [49] Drawbacks to stem cell therapy in cardiovascular diseases
    Wang, Chao-Hung
    Cherng, Wen-Jin
    Verma, Subodh
    FUTURE CARDIOLOGY, 2008, 4 (04) : 399 - 408
  • [50] Mesenchymal Stem Cell Therapy in Nonhematopoietic Diseases
    Teixeira de Carvalho, Katherine Athayde
    Steinhoff, Gustav
    Chachques, Juan Carlos
    STEM CELLS INTERNATIONAL, 2015, 2015